In relapsed pancreatic cancer, a phase III clinical trial showed no statistical difference between FOLFOX (folinic acid + fluorouracil + oxaliplatin) in association with pegylated IL-10 compared to FOLFOX alone [62]. This evidence concerns the gene IL10 and familial pancreatic carcinoma.